A360
Key Takeaways✦ Atlas AI
01
Mifepristone access extended temporarily.
02
Supreme Court deliberates emergency appeal.
03
5th Circuit ruling remains on hold.
Atlas AI
The U.S. Supreme Court on Monday, May 11, 2026, extended a temporary order that allows patients to continue obtaining the abortion pill mifepristone through telehealth visits and mail delivery. The move keeps current access rules in place while the justices consider emergency appeals over the drug’s availability. Justice Samuel Alito issued the extension, which runs until Thursday, May 14, at 5 p.m. ET.
The order pauses enforcement of a May 1 ruling by the 5th U.S. Circuit Court of Appeals that would have required patients to obtain mifepristone through in-person visits. As is typical for an administrative stay, the order provided no explanation.
The dispute is one of the most significant abortion-related cases to reach the court since the 2022 decision overturning Roe v. Wade. After that ruling, demand for medication abortion increased in states that banned in-clinic abortions, raising the stakes for access to mifepristone.
Louisiana lawsuit challenges FDA telehealth policy
The legal challenge stems from a lawsuit filed by Louisiana against the Food and Drug Administration over the agency’s policy allowing telehealth access to mifepristone. The state argued the regulation undermined its abortion ban.
A federal district court in April partially sided with Louisiana, concluding the FDA’s policy was arbitrary and capricious because the agency lacked adequate data to judge the drug’s safety. The district court delayed implementation of its decision to give the FDA time to complete a review of the drug.
Drugmakers warn of nationwide disruption
Earlier this month, a three-judge panel of the 5th Circuit put the FDA’s mifepristone rule on hold immediately. The decision meant patients seeking the drug were abruptly required to obtain it through in-person visits.
Danco Laboratories, which makes mifepristone, filed an emergency appeal at the Supreme Court on May 2, warning of chaos and disruption. GenBioPro, which makes a generic version of the drug, filed a separate appeal and said the 5th Circuit ruling risked cutting off access for patients nationwide.
The Supreme Court’s temporary order does not decide the case’s merits. The next deadline arrives Thursday, when the administrative stay is set to expire unless the court extends it again or issues a further order.
